Menu
PhoenixzaTM is a multi-platform tumor profiling test which unravels the molecular and functional status of the cancer to identify and insightfully target the tumor's vulnerabilities.
PhoenixzaTM provides direct tumor derived evidence which enables the physician to customize treatment options for each patient with unprecedented precision to reduce the risk of treatment failure as well as toxicities.
The clinical utility of PhoenixzaTM has been ascertained through a Phase - II / III open label single arm clinical trial.
PFS (at 90 days): 93.9%, DCR: 90.5% and ORR: 42.9%.
Through personalized treatment / targeted therapy, physicians can select drugs that are more likely to be effective based on the patient’s genetic makeup and molecular profile.
Phase – II / III open-label single arm clinical trial (CTRI/2018/02/011808).
